A carregar...
A perspective on anti-EGFR therapies targeting triple-negative breast cancer
Triple-negative breast cancer (TNBC), which lacks estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), accounts for about 15-20% of breast cancers and is the most aggressive breast cancer subtype. There are currently no effective therapies against...
Na minha lista:
| Publicado no: | Am J Cancer Res |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
e-Century Publishing Corporation
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5004067/ https://ncbi.nlm.nih.gov/pubmed/27648353 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|